A new study, published in Nature Communications, conducted by the University of Liverpool and the Johns Hopkins University School of Medicine highlights a new ‘long acting’ medicine for the prevention of malaria.
Every year, malaria afflicts hundreds of millions of people and kills hundreds of thousands of children. Despite considerable success in reducing the worldwide prevalence of malaria, its incidence in visitors to endemic areas has continued to rise steadily.
Currently, the best available prevention of malaria requires oral dosing of antimalarial tablets. Chronic oral dosing of these medicines has significant complications because healthy people need to strictly adhere to the medication in order for effective prophylaxis to occur.
The study, led by Pharmacologist Professor Andrew Owen and Materials Chemist Professor Steve Rannard, aimed to utilise nanotechnology to improve the delivery of an existing antimalarial drug via a novel injectable format that can maintain blood concentration of the drug for weeks or months following a single dose.
Nanotechnology is the manipulation of matter on an atomic, molecular, and supramolecular scale. Nanomedicine is the application of nanotechnology to the diagnosis, prevention or treatment of disease in the human body.
Solid Drug Nanoparticles (SDNs) are a nanotechnology with favourable characteristics to enhance drug exposure and improve the treatment or prevention of several diseases, including HIV and malaria.
The Liverpool team have previously shown SDNs to be effective for oral delivery of drugs, but this is the first time they have shown benefits for a long-acting injectable (LAI) format. These particles have an approximate diameter that is 1/500th the width of a human hair, and once injected into the muscle, establish a drug depot that releases drug into the bloodstream over an extended period of time.
Through the use of this technology the trans-Atlantic research team developed an LAI version of a daily anti-malarial tablet (atovaquone) which provided prophylactic blood concentrations in mice for a period of 28 days. Moreover, mice injected with the nanomedicine were completely protected from the malaria parasite when exposed during this time, and since mice eliminate the drug much more rapidly in humans, a much longer duration of protection might be expected in people.
Impacting large numbers
Professor Rannard, said: “Although anti-malaria drugs exist they require individuals to take medication daily. Chronic oral dosing has significant complications that arise from the high pill burden experienced by many patients across populations with varying conditions leading to non-adherence to preventative therapies.
“Our research seeks to remove the need for daily tablets and generate long-acting dosing technologies that may be able to provide therapeutic drug concentrations for months after a single administration. This would provide a clinically-relevant intervention that could readily impact large numbers of people and significantly prevent the transmission of malaria.”
Professor Owen, added “The ability of this nanomedicine to protect from infection by malaria may provide an additional tool in the global arsenal used to combat malaria in non-immune travellers and ultimately people who live in endemic areas of the world. Since atovaquone is already licenced for use in humans and the nanomedicine contains ingredients already used in other medicines, it could be enter clinical trials within a very short timescale”
“If other drugs can be manufactured in this way, in the longer term there is also potential for a long-acting combination therapy for malaria.”
The full study, entitled ‘Long-acting injectable atovaquone nanomedicines for malaria prophylaxis’, can be found here.
For further information about nano-medicine please listen to the University of Liverpool podcast featuring Professors Rannard and Owen which can be found here.
The Latest on: Solid Drug Nanoparticles
via Google News
The Latest on: Solid Drug Nanoparticles
- The Use of Biochemistry within Biotechnologyon August 20, 2021 at 11:33 am
Several enzyme immobilization methods have been developed that allow recovery and reuse, including flat solid supports and particulate supports, in the form of microbeads or nanoparticles ...
- Nanoparticles for Imaging and Treating Brain Canceron August 17, 2021 at 5:00 pm
solid lipid nanoparticles [among nanosized drug carriers]) are in preclinical research for CNS delivery; with the exception of polymeric drugs, no products based on these platforms are on the ...
- Self-nanoemulsifying Drug Delivery Systems: Formulation Insights, Applications and Advanceson August 17, 2021 at 5:00 pm
and drug nanoparticles or nanosuspensions.  Lipid nanocarriers include lipid core micelles, liposomes, microemulsions, nanoemulsions, solid lipid nanoparticles and nanostructured lipid carriers ...
- Scientists develop non-invasive bio-nanocarrier visceral leishmaniasis therapyon August 17, 2021 at 3:48 am
Anchoring Vitamin B12 on the surface of solid lipid nanoparticles augmented the stability and targeted delivery of the poorly soluble drugs and also enhanced the therapeutic efficiency with ...
- Non-invasive, easy to administer, cost-effective bio-nanocarrier can enhance oral bioavailability and efficacy of Visceral leishmaniasis therapyon August 16, 2021 at 11:25 am
Indian researchers have developed a non-invasive, easy to administer, cost-effective, and patient compliant potential therapeutic strategy against Visceral leishmaniasis, a neglected tropical disease.
- Creative Pushback Against Burnout; Novel Drug Delivery; Good News for Cervical Canceron August 13, 2021 at 9:01 am
Charles Bankhead, Senior Editor, MedPage Today August 12, 2021 An oncologist describes how she uses her creative outlet to counter burnout. ( ASCO Connection) In preclinical studies involving mice, ...
- Seeking signals seeping through poreson August 13, 2021 at 6:41 am
Todd Squires Enlarge image Researchers in the US and Saudi Arabia have developed a procedure to make small objects, such as oil droplets or solid nanoparticles ... include delivering diagnostic or ...
- Gold Nanoparticles for Targeted Gastric Cancer Therapyon August 13, 2021 at 4:28 am
New gold based-targeted drug delivery ... Using nanoparticles, scientists have developed a new way to deliver treatments directly to neuroblastoma - the most common solid childhood cancer.
- Nanoparticles Help Treat Common Childhood Canceron July 29, 2021 at 3:18 am
New way to deliver drugs that can ... is the most common solid tumour found in children and accounts for about 15% of all cancer-related deaths in children. ‘Nanoparticles, delivered via ...
via Bing News